NASDAQ:KTRA Kintara Therapeutics (KTRA) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free KTRA Stock Alerts $0.09 0.00 (0.00%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$0.09▼$0.0950-Day Range$0.08▼$0.1552-Week Range$0.08▼$5.98Volume3.79 million shsAverage Volume11.52 million shsMarket Capitalization$3.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Kintara Therapeutics alerts: Email Address Kintara Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish5.64% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.06Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.48) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.12 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Kintara Therapeutics. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.64% of the outstanding shares of Kintara Therapeutics have been sold short.Short Interest Ratio / Days to CoverKintara Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kintara Therapeutics has recently increased by 0.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKintara Therapeutics does not currently pay a dividend.Dividend GrowthKintara Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KTRA. Previous Next 2.8 News and Social Media Coverage News SentimentKintara Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kintara Therapeutics this week, compared to 0 articles on an average week.Search Interest43 people have searched for KTRA on MarketBeat in the last 30 days. This is an increase of 95% compared to the previous 30 days.MarketBeat Follows8 people have added Kintara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kintara Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.83% of the stock of Kintara Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 0.62% of the stock of Kintara Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kintara Therapeutics are expected to grow in the coming year, from ($2.48) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kintara Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kintara Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Kintara Therapeutics Stock (NASDAQ:KTRA)Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.Read More KTRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KTRA Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comKintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on PembrolizumabMarch 27, 2024 | prnewswire.comKintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on PembrolizumabMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 15, 2024 | nasdaq.comKintara Therapeutics Bounces BackFebruary 21, 2024 | uk.investing.comKintara Therapeutics Inc (KTRA)February 20, 2024 | uk.investing.comMyMD Pharmaceuticals Inc (0A8D)February 14, 2024 | finance.yahoo.comKintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate UpdateFebruary 14, 2024 | prnewswire.comKintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate UpdateMarch 28, 2024 | Huge Alerts (Ad)Trending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! February 12, 2024 | finance.yahoo.comKintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast CancerFebruary 1, 2024 | msn.comPanbela Therapeutics closes ~$9M public offering of sharesDecember 7, 2023 | markets.businessinsider.comKintara Announces Review Of Strategic Alternatives To Maximize Stockholder ValueDecember 7, 2023 | finance.yahoo.comKintara Therapeutics Announces Review of Strategic AlternativesNovember 28, 2023 | ca.finance.yahoo.comKintara Therapeutics Inc (3DMA.BE)November 16, 2023 | morningstar.comKintara Therapeutics Inc KTRANovember 13, 2023 | finance.yahoo.comKintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate UpdateNovember 1, 2023 | benzinga.comWhy Kintara Therapeutics (KTRA) Shares Are Getting ObliteratedOctober 31, 2023 | marketwatch.comKintara Therapeutics Shares Plumb New Depths on VAL-083 FailureOctober 31, 2023 | marketwatch.comKintara Says Glioblastoma Treatment Candidate Shows Little PromiseOctober 31, 2023 | marketwatch.comKintara Shares Down 72% After Suspending Glioblastoma Drug DevelopmentOctober 31, 2023 | markets.businessinsider.comKintara Therapeutics Suspends Development Of VAL-083 In Glioblastoma; Stock DropsOctober 11, 2023 | finance.yahoo.comKintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth ConferenceOctober 2, 2023 | finance.yahoo.comKintara Therapeutics to Present at the LD Micro Main Event XVI ConferenceSeptember 25, 2023 | finance.yahoo.comKintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual MeetingSeptember 19, 2023 | seekingalpha.comKintara Therapeutics Non-GAAP EPS of -$9.27September 18, 2023 | finance.yahoo.comKintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate UpdateSeptember 14, 2023 | uk.finance.yahoo.comKTRA - Kintara Therapeutics, Inc.See More Headlines Receive KTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KTRA CUSIPN/A CIK1498382 Webwww.kintara.com Phone(858) 350-4364Fax604-608-5685Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,650,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-305.69% Debt Debt-to-Equity RatioN/A Current Ratio0.63 Quick Ratio0.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($5.86) per share Price / Book-0.02Miscellaneous Outstanding Shares39,038,000Free Float37,152,000Market Cap$3.49 million OptionableNot Optionable Beta0.59 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Jeffrey A. Bacha B.Sc. (Age 56)M.B.A., Founder Mr. Greg A. JohnsonActing Head of OperationsKey CompetitorsJaguar HealthNASDAQ:JAGXPhaseBio PharmaceuticalsNASDAQ:PHASAridis PharmaceuticalsNASDAQ:ARDSPetros PharmaceuticalsNASDAQ:PTPIPaxMedicaNASDAQ:PXMDView All Competitors KTRA Stock Analysis - Frequently Asked Questions Should I buy or sell Kintara Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KTRA shares. View KTRA analyst ratings or view top-rated stocks. How have KTRA shares performed in 2024? Kintara Therapeutics' stock was trading at $0.1696 at the start of the year. Since then, KTRA stock has decreased by 47.2% and is now trading at $0.0895. View the best growth stocks for 2024 here. When is Kintara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our KTRA earnings forecast. How were Kintara Therapeutics' earnings last quarter? Kintara Therapeutics, Inc. (NASDAQ:KTRA) released its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.24) earnings per share (EPS) for the quarter. When did Kintara Therapeutics' stock split? Kintara Therapeutics shares reverse split before market open on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Kintara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN). How do I buy shares of Kintara Therapeutics? Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KTRA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kintara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.